实验性淋球菌脂寡糖模拟肽疫苗的疗效需要末端补体。
Efficacy of an Experimental Gonococcal Lipooligosaccharide Mimitope Vaccine Requires Terminal Complement.
机构信息
Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Systems Immunity Research Institute and Dementia Research Institute, Henry Wellcome Building for Biomedical Research, Cardiff University, Heath Park, Cardiff, United Kingdom.
出版信息
J Infect Dis. 2022 May 16;225(10):1861-1864. doi: 10.1093/infdis/jiab630.
Abstract
A safe and effective vaccine against multidrug-resistant gonorrhea is urgently needed. An experimental peptide vaccine called TMCP2 that mimics an oligosaccharide epitope in gonococcal lipooligosaccharide, when adjuvanted with glucopyranosyl lipid adjuvant-stable emulsion, elicits bactericidal immunoglobulin G and hastens clearance of gonococci in the mouse vaginal colonization model. In this study, we show that efficacy of TMCP2 requires an intact terminal complement pathway, evidenced by loss of activity in C9-/- mice or when C7 function was blocked. In conclusion, TMCP2 vaccine efficacy in the mouse vagina requires membrane attack complex. Serum bactericidal activity may serve as a correlate of protection for TMCP2.
摘要
急需一种安全有效的针对耐多药淋病的疫苗。一种名为 TMCP2 的实验性肽疫苗模拟淋球菌脂寡糖中的寡糖表位，当与葡萄糖基脂质佐剂稳定乳剂佐剂时，可引发杀菌性免疫球蛋白 G，并加速清除小鼠阴道定植模型中的淋病奈瑟菌。在这项研究中，我们表明 TMCP2 的功效需要完整的末端补体途径，这一点可以从 C9-/- 小鼠或 C7 功能被阻断时的活性丧失中得到证明。总之，TMCP2 疫苗在小鼠阴道中的功效需要膜攻击复合物。血清杀菌活性可能是 TMCP2 保护作用的一个相关指标。
相似文献
1
Efficacy of an Experimental Gonococcal Lipooligosaccharide Mimitope Vaccine Requires Terminal Complement.实验性淋球菌脂寡糖模拟肽疫苗的疗效需要末端补体。
J Infect Dis. 2022 May 16;225(10):1861-1864. doi: 10.1093/infdis/jiab630.
2
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.脂寡糖肽模拟候选淋病球菌疫苗的临床前疗效。
mBio. 2019 Nov 5;10(6):e02552-19. doi: 10.1128/mBio.02552-19.
3
Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection.合成 DNA 传递优化和工程化的单克隆抗体可快速持久地提供针对实验性淋球菌感染的保护。
mBio. 2021 Mar 16;12(2):e00242-21. doi: 10.1128/mBio.00242-21.
4
Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine.针对淋病奈瑟菌脂寡糖（LOS）的疫苗目标。
Front Immunol. 2019 Feb 27;10:321. doi: 10.3389/fimmu.2019.00321. eCollection 2019.
5
Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection.免疫接种针对糖表位可加速清除实验性淋球菌感染。
PLoS Pathog. 2013;9(8):e1003559. doi: 10.1371/journal.ppat.1003559. Epub 2013 Aug 29.
6
Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence.人工智能鉴定的细胞分裂蛋白候选淋病疫苗的临床前疗效。
mBio. 2023 Dec 19;14(6):e0250023. doi: 10.1128/mbio.02500-23. Epub 2023 Oct 31.
7
Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.淋病菌脂寡糖唾液酸化：毒力因子及新型免疫疗法的靶点
Pathog Dis. 2017 Jun 1;75(4). doi: 10.1093/femspd/ftx049.
8
Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody.补体单独驱动嵌合抗淋球菌单克隆抗体的疗效。
PLoS Biol. 2019 Jun 19;17(6):e3000323. doi: 10.1371/journal.pbio.3000323. eCollection 2019 Jun.
9
An optimized Factor H-Fc fusion protein against multidrug-resistant .一种针对多重耐药性的优化因子 H-Fc 融合蛋白。
Front Immunol. 2022 Aug 30;13:975676. doi: 10.3389/fimmu.2022.975676. eCollection 2022.
10
The Lst Sialyltransferase of Neisseria gonorrhoeae Can Transfer Keto-Deoxyoctanoate as the Terminal Sugar of Lipooligosaccharide: a Glyco-Achilles Heel That Provides a New Strategy for Vaccines to Prevent Gonorrhea.淋病奈瑟菌的最后一个唾液酸转移酶可以将酮-脱氧辛酮酸作为脂寡糖的末端糖转移：这是一个聚糖阿喀琉斯之踵，为预防淋病的疫苗提供了新策略。
mBio. 2021 Mar 23;12(2):e03666-20. doi: 10.1128/mBio.03666-20.
引用本文的文献
1
A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.一种新型的基于颗粒性脑膜炎球菌疫苗（GMMA）的淋球菌疫苗在小鼠中显示出功能性免疫反应。
NPJ Vaccines. 2025 Jul 5;10(1):146. doi: 10.1038/s41541-025-01190-1.
2
In Vitro Pre-Clinical Evaluation of a Gonococcal Trivalent Candidate Vaccine Identified by Transcriptomics.通过转录组学鉴定的淋球菌三价候选疫苗的体外临床前评估
Vaccines (Basel). 2023 Dec 13;11(12):1846. doi: 10.3390/vaccines11121846.
3
Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved SliC antigen that blocks human lysozyme.开发一种标签/捕获介导的衣壳病毒样颗粒疫苗，展示保守的 SliC 抗原，该抗原可阻断人溶菌酶。
Infect Immun. 2023 Dec 12;91(12):e0024523. doi: 10.1128/iai.00245-23. Epub 2023 Nov 2.
4
Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy.Th1 极化 MtrE 基淋病奈瑟菌疫苗具有预防和治疗功效。
Emerg Microbes Infect. 2023 Dec;12(2):2249124. doi: 10.1080/22221751.2023.2249124.
5
Vertebrate and Invertebrate Animal and New In Vitro Models for Studying Biology.用于研究生物学的脊椎动物和无脊椎动物及新型体外模型。
Pathogens. 2023 May 30;12(6):782. doi: 10.3390/pathogens12060782.
本文引用的文献
1
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species.能够在多个物种中抑制C5下游补体的单克隆抗体。
Front Immunol. 2020 Dec 10;11:612402. doi: 10.3389/fimmu.2020.612402. eCollection 2020.
2
Requirement of Complement C6 for Intact Innate Immune Responses in Mice.补体 C6 对于小鼠完整固有免疫反应的需求。
J Immunol. 2020 Jul 1;205(1):251-260. doi: 10.4049/jimmunol.1900801. Epub 2020 May 22.
3
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.脂寡糖肽模拟候选淋病球菌疫苗的临床前疗效。
mBio. 2019 Nov 5;10(6):e02552-19. doi: 10.1128/mBio.02552-19.
4
Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.多组分脑膜炎奈瑟菌 B 型（MenB）-4C 疫苗可诱导补体缺陷儿童产生有效的调理吞噬杀伤作用。
Clin Exp Immunol. 2019 Dec;198(3):381-389. doi: 10.1111/cei.13368. Epub 2019 Oct 1.
5
Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody.补体单独驱动嵌合抗淋球菌单克隆抗体的疗效。
PLoS Biol. 2019 Jun 19;17(6):e3000323. doi: 10.1371/journal.pbio.3000323. eCollection 2019 Jun.
6
Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.携带非典型溶血性综合征相关因子 H 突变的小鼠中 C5aR 和 C5b-9 途径对肾脏血栓性微血管病和大血管血栓形成的差异贡献。
Kidney Int. 2019 Jul;96(1):67-79. doi: 10.1016/j.kint.2019.01.009. Epub 2019 Feb 27.
7
Gonococcal Defenses against Antimicrobial Activities of Neutrophils.淋球菌抵抗中性粒细胞抗菌活性的机制。
Trends Microbiol. 2018 Dec;26(12):1022-1034. doi: 10.1016/j.tim.2018.07.003. Epub 2018 Aug 13.
8
Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development.淋病奈瑟菌：耐药性、小鼠模型和疫苗开发。
Annu Rev Microbiol. 2017 Sep 8;71:665-686. doi: 10.1146/annurev-micro-090816-093530.
9
Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.新西兰 B 群脑膜炎球菌外膜囊泡疫苗预防淋病的效果：一项回顾性病例对照研究。
Lancet. 2017 Sep 30;390(10102):1603-1610. doi: 10.1016/S0140-6736(17)31449-6. Epub 2017 Jul 10.
10
Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.依库珠单抗治疗与免疫成人全血对脑膜炎球菌调理吞噬杀伤作用受损
Blood. 2017 Aug 17;130(7):891-899. doi: 10.1182/blood-2017-05-781450. Epub 2017 Jun 19.
Zotero 插件